Novel NMP split liver model recapitulates human IRI and demonstrates ferroptosis modulators as a new therapeutic strategy
Background Almost 9%of deceased donor livers are discarded as marginal donor livers (MDL) due to concern of severe ischemia reperfusion injury (IRI). Emerging data supports ferroptosis (iron regulated hepatocellular death) as an IRI driver, however lack of robust preclinical model limits therapeutic...
Gespeichert in:
| Veröffentlicht in: | Pediatric transplantation 2022-03, Vol.26 (2), p.e14164-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 2 |
| container_start_page | e14164 |
| container_title | Pediatric transplantation |
| container_volume | 26 |
| creator | Nazzal, Mustafa Madsen, Erik C. Armstrong, Austin Nispen, Johan Murali, Vidul Song, Eric Voigt, Marcus Madnawat, Himani Welu, Adam Manithody, Chandrashekhara Suri, Anandini Krebs, Joseph Gilbert, Ester Samaddar, Ashish Blackall, Douglas Carpenter, Danielle Varma, Chintalapati Teckman, Jeffrey Jain, Ajay Kumar |
| description | Background
Almost 9%of deceased donor livers are discarded as marginal donor livers (MDL) due to concern of severe ischemia reperfusion injury (IRI). Emerging data supports ferroptosis (iron regulated hepatocellular death) as an IRI driver, however lack of robust preclinical model limits therapeutic testing. In this manuscript we describe the development of a novel rigorous internal control system utilizing normothermic perfusion of split livers to test ferroptosis regulators modulating IRI.
Methods
Upon institutional approval, split human MDLs were placed on our normothermic perfusion machine, Perfusion Regulated Organ Therapeutics with Enhanced Controlled Testing (PROTECT), pumping arterial and portal blood. Experiment 1 compared right (UR) and left (UL) lobes to validate PROTECT. Experiment 2 assessed ferroptosis regulator Deferoxamine in Deferoxamine Agent Treated (DMAT) vs. No Agent Internal Control (NAIC) lobes. Liver serology, histology, and ferroptosis genes were assessed.
Results
Successful MDL perfusion validated PROTECT with no ALT or AST difference between UR and UL (∆ALT UR: 235, ∆ALT UL: 212; ∆AST UR: 576, ∆AST UL: 389). Liver injury markers increased in NAIC vs. DMAT (∆ALT NAIC: 586, ∆ALT DMAT: ‐405; ∆AST NAIC: 617, ∆AST DMAT: ‐380). UR and UL had similar expression of ferroptosis regulators RPL8,HO‐1 and HIFα. Significantly decreased intrahepatic iron (p = .038), HO‐1 and HIFα in DMAT (HO‐1 NAIC: 6.93, HO‐1 DMAT: 2.74; HIFαNAIC: 8.67, HIFαDMAT: 2.60)and no hepatocellular necrosis or immunohistochemical staining (Ki67/Cytokeratin‐7) differences were noted.
Conclusion
PROTECT demonstrates the therapeutic utility of a novel normothermic perfusion split liver system for drug discovery and rapid translatability of therapeutics, driving a paradigm change in organ recovery and transplant medicine. Our study using human livers, provides preliminary proof of concept for the novel role of ferroptosis regulators in driving IRI. |
| doi_str_mv | 10.1111/petr.14164 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2580940158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2626169580</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3574-a2f7c442127bcf28ef4e7aadd3a0cae0ab1d4aa04e798788afe6910883f22c993</originalsourceid><addsrcrecordid>eNp9kV9r2zAUxcVYWbp2L_sARbCXMnCrf7HlxxGyNdC1pXTP4ka-blxsy5PklHz7KnHXhz7sIrji6HcOgkPIV84ueJrLAaO_4Irn6gM55rIsM8lU_vFwLzLJlZiRzyE8MZYQrT6RmVS5lFyyY7K7cVts6c3vOxqGtom0bbboaeeqpHq0MDRxbCFioJuxg56u7lcU-opW2Lk-RH94qtF7N0QXmrC37g3OBwrp0B6fadyghwHH2Fg6eR53p-Sohjbgl9d9Qv78XD4srrLr21-rxY_rzMp5oTIQdWGVElwUa1sLjbXCAqCqJDALyGDNKwXAklrqQmuoMS8501rWQtiylCfkfModvPs7Yoima4LFtoUe3RiMmGtWKsbnOqHf3qFPbvR9-p0Ruch5XiY2Ud8nynoXgsfaDL7pwO8MZ2ZfiNkXYg6FJPjsNXJcd1i9of8aSACfgOemxd1_oszd8uF-Cn0BWxWX4A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2626169580</pqid></control><display><type>article</type><title>Novel NMP split liver model recapitulates human IRI and demonstrates ferroptosis modulators as a new therapeutic strategy</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Nazzal, Mustafa ; Madsen, Erik C. ; Armstrong, Austin ; Nispen, Johan ; Murali, Vidul ; Song, Eric ; Voigt, Marcus ; Madnawat, Himani ; Welu, Adam ; Manithody, Chandrashekhara ; Suri, Anandini ; Krebs, Joseph ; Gilbert, Ester ; Samaddar, Ashish ; Blackall, Douglas ; Carpenter, Danielle ; Varma, Chintalapati ; Teckman, Jeffrey ; Jain, Ajay Kumar</creator><creatorcontrib>Nazzal, Mustafa ; Madsen, Erik C. ; Armstrong, Austin ; Nispen, Johan ; Murali, Vidul ; Song, Eric ; Voigt, Marcus ; Madnawat, Himani ; Welu, Adam ; Manithody, Chandrashekhara ; Suri, Anandini ; Krebs, Joseph ; Gilbert, Ester ; Samaddar, Ashish ; Blackall, Douglas ; Carpenter, Danielle ; Varma, Chintalapati ; Teckman, Jeffrey ; Jain, Ajay Kumar</creatorcontrib><description>Background
Almost 9%of deceased donor livers are discarded as marginal donor livers (MDL) due to concern of severe ischemia reperfusion injury (IRI). Emerging data supports ferroptosis (iron regulated hepatocellular death) as an IRI driver, however lack of robust preclinical model limits therapeutic testing. In this manuscript we describe the development of a novel rigorous internal control system utilizing normothermic perfusion of split livers to test ferroptosis regulators modulating IRI.
Methods
Upon institutional approval, split human MDLs were placed on our normothermic perfusion machine, Perfusion Regulated Organ Therapeutics with Enhanced Controlled Testing (PROTECT), pumping arterial and portal blood. Experiment 1 compared right (UR) and left (UL) lobes to validate PROTECT. Experiment 2 assessed ferroptosis regulator Deferoxamine in Deferoxamine Agent Treated (DMAT) vs. No Agent Internal Control (NAIC) lobes. Liver serology, histology, and ferroptosis genes were assessed.
Results
Successful MDL perfusion validated PROTECT with no ALT or AST difference between UR and UL (∆ALT UR: 235, ∆ALT UL: 212; ∆AST UR: 576, ∆AST UL: 389). Liver injury markers increased in NAIC vs. DMAT (∆ALT NAIC: 586, ∆ALT DMAT: ‐405; ∆AST NAIC: 617, ∆AST DMAT: ‐380). UR and UL had similar expression of ferroptosis regulators RPL8,HO‐1 and HIFα. Significantly decreased intrahepatic iron (p = .038), HO‐1 and HIFα in DMAT (HO‐1 NAIC: 6.93, HO‐1 DMAT: 2.74; HIFαNAIC: 8.67, HIFαDMAT: 2.60)and no hepatocellular necrosis or immunohistochemical staining (Ki67/Cytokeratin‐7) differences were noted.
Conclusion
PROTECT demonstrates the therapeutic utility of a novel normothermic perfusion split liver system for drug discovery and rapid translatability of therapeutics, driving a paradigm change in organ recovery and transplant medicine. Our study using human livers, provides preliminary proof of concept for the novel role of ferroptosis regulators in driving IRI.</description><identifier>ISSN: 1397-3142</identifier><identifier>EISSN: 1399-3046</identifier><identifier>DOI: 10.1111/petr.14164</identifier><identifier>PMID: 34633130</identifier><language>eng</language><publisher>Denmark: Wiley Subscription Services, Inc</publisher><subject>Cytokeratin ; Deferoxamine ; Donor Selection ; Ferroptosis ; Graft Survival ; Humans ; Immunomodulation ; In Vitro Techniques ; Iron ; Ischemia ; ischemia reperfusion injury ; Liver ; Liver - blood supply ; Liver Function Tests ; liver transplant ; Liver Transplantation ; Liver transplants ; Organ Preservation - methods ; Organ removal ; Perfusion ; Perfusion - methods ; Reperfusion ; Reperfusion Injury - prevention & control ; Serology</subject><ispartof>Pediatric transplantation, 2022-03, Vol.26 (2), p.e14164-n/a</ispartof><rights>2021 Wiley Periodicals LLC</rights><rights>2021 Wiley Periodicals LLC.</rights><rights>2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3574-a2f7c442127bcf28ef4e7aadd3a0cae0ab1d4aa04e798788afe6910883f22c993</citedby><cites>FETCH-LOGICAL-c3574-a2f7c442127bcf28ef4e7aadd3a0cae0ab1d4aa04e798788afe6910883f22c993</cites><orcidid>0000-0002-9420-5722 ; 0000-0002-8437-6085</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fpetr.14164$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fpetr.14164$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34633130$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nazzal, Mustafa</creatorcontrib><creatorcontrib>Madsen, Erik C.</creatorcontrib><creatorcontrib>Armstrong, Austin</creatorcontrib><creatorcontrib>Nispen, Johan</creatorcontrib><creatorcontrib>Murali, Vidul</creatorcontrib><creatorcontrib>Song, Eric</creatorcontrib><creatorcontrib>Voigt, Marcus</creatorcontrib><creatorcontrib>Madnawat, Himani</creatorcontrib><creatorcontrib>Welu, Adam</creatorcontrib><creatorcontrib>Manithody, Chandrashekhara</creatorcontrib><creatorcontrib>Suri, Anandini</creatorcontrib><creatorcontrib>Krebs, Joseph</creatorcontrib><creatorcontrib>Gilbert, Ester</creatorcontrib><creatorcontrib>Samaddar, Ashish</creatorcontrib><creatorcontrib>Blackall, Douglas</creatorcontrib><creatorcontrib>Carpenter, Danielle</creatorcontrib><creatorcontrib>Varma, Chintalapati</creatorcontrib><creatorcontrib>Teckman, Jeffrey</creatorcontrib><creatorcontrib>Jain, Ajay Kumar</creatorcontrib><title>Novel NMP split liver model recapitulates human IRI and demonstrates ferroptosis modulators as a new therapeutic strategy</title><title>Pediatric transplantation</title><addtitle>Pediatr Transplant</addtitle><description>Background
Almost 9%of deceased donor livers are discarded as marginal donor livers (MDL) due to concern of severe ischemia reperfusion injury (IRI). Emerging data supports ferroptosis (iron regulated hepatocellular death) as an IRI driver, however lack of robust preclinical model limits therapeutic testing. In this manuscript we describe the development of a novel rigorous internal control system utilizing normothermic perfusion of split livers to test ferroptosis regulators modulating IRI.
Methods
Upon institutional approval, split human MDLs were placed on our normothermic perfusion machine, Perfusion Regulated Organ Therapeutics with Enhanced Controlled Testing (PROTECT), pumping arterial and portal blood. Experiment 1 compared right (UR) and left (UL) lobes to validate PROTECT. Experiment 2 assessed ferroptosis regulator Deferoxamine in Deferoxamine Agent Treated (DMAT) vs. No Agent Internal Control (NAIC) lobes. Liver serology, histology, and ferroptosis genes were assessed.
Results
Successful MDL perfusion validated PROTECT with no ALT or AST difference between UR and UL (∆ALT UR: 235, ∆ALT UL: 212; ∆AST UR: 576, ∆AST UL: 389). Liver injury markers increased in NAIC vs. DMAT (∆ALT NAIC: 586, ∆ALT DMAT: ‐405; ∆AST NAIC: 617, ∆AST DMAT: ‐380). UR and UL had similar expression of ferroptosis regulators RPL8,HO‐1 and HIFα. Significantly decreased intrahepatic iron (p = .038), HO‐1 and HIFα in DMAT (HO‐1 NAIC: 6.93, HO‐1 DMAT: 2.74; HIFαNAIC: 8.67, HIFαDMAT: 2.60)and no hepatocellular necrosis or immunohistochemical staining (Ki67/Cytokeratin‐7) differences were noted.
Conclusion
PROTECT demonstrates the therapeutic utility of a novel normothermic perfusion split liver system for drug discovery and rapid translatability of therapeutics, driving a paradigm change in organ recovery and transplant medicine. Our study using human livers, provides preliminary proof of concept for the novel role of ferroptosis regulators in driving IRI.</description><subject>Cytokeratin</subject><subject>Deferoxamine</subject><subject>Donor Selection</subject><subject>Ferroptosis</subject><subject>Graft Survival</subject><subject>Humans</subject><subject>Immunomodulation</subject><subject>In Vitro Techniques</subject><subject>Iron</subject><subject>Ischemia</subject><subject>ischemia reperfusion injury</subject><subject>Liver</subject><subject>Liver - blood supply</subject><subject>Liver Function Tests</subject><subject>liver transplant</subject><subject>Liver Transplantation</subject><subject>Liver transplants</subject><subject>Organ Preservation - methods</subject><subject>Organ removal</subject><subject>Perfusion</subject><subject>Perfusion - methods</subject><subject>Reperfusion</subject><subject>Reperfusion Injury - prevention & control</subject><subject>Serology</subject><issn>1397-3142</issn><issn>1399-3046</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kV9r2zAUxcVYWbp2L_sARbCXMnCrf7HlxxGyNdC1pXTP4ka-blxsy5PklHz7KnHXhz7sIrji6HcOgkPIV84ueJrLAaO_4Irn6gM55rIsM8lU_vFwLzLJlZiRzyE8MZYQrT6RmVS5lFyyY7K7cVts6c3vOxqGtom0bbboaeeqpHq0MDRxbCFioJuxg56u7lcU-opW2Lk-RH94qtF7N0QXmrC37g3OBwrp0B6fadyghwHH2Fg6eR53p-Sohjbgl9d9Qv78XD4srrLr21-rxY_rzMp5oTIQdWGVElwUa1sLjbXCAqCqJDALyGDNKwXAklrqQmuoMS8501rWQtiylCfkfModvPs7Yoima4LFtoUe3RiMmGtWKsbnOqHf3qFPbvR9-p0Ruch5XiY2Ud8nynoXgsfaDL7pwO8MZ2ZfiNkXYg6FJPjsNXJcd1i9of8aSACfgOemxd1_oszd8uF-Cn0BWxWX4A</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Nazzal, Mustafa</creator><creator>Madsen, Erik C.</creator><creator>Armstrong, Austin</creator><creator>Nispen, Johan</creator><creator>Murali, Vidul</creator><creator>Song, Eric</creator><creator>Voigt, Marcus</creator><creator>Madnawat, Himani</creator><creator>Welu, Adam</creator><creator>Manithody, Chandrashekhara</creator><creator>Suri, Anandini</creator><creator>Krebs, Joseph</creator><creator>Gilbert, Ester</creator><creator>Samaddar, Ashish</creator><creator>Blackall, Douglas</creator><creator>Carpenter, Danielle</creator><creator>Varma, Chintalapati</creator><creator>Teckman, Jeffrey</creator><creator>Jain, Ajay Kumar</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-9420-5722</orcidid><orcidid>https://orcid.org/0000-0002-8437-6085</orcidid></search><sort><creationdate>202203</creationdate><title>Novel NMP split liver model recapitulates human IRI and demonstrates ferroptosis modulators as a new therapeutic strategy</title><author>Nazzal, Mustafa ; Madsen, Erik C. ; Armstrong, Austin ; Nispen, Johan ; Murali, Vidul ; Song, Eric ; Voigt, Marcus ; Madnawat, Himani ; Welu, Adam ; Manithody, Chandrashekhara ; Suri, Anandini ; Krebs, Joseph ; Gilbert, Ester ; Samaddar, Ashish ; Blackall, Douglas ; Carpenter, Danielle ; Varma, Chintalapati ; Teckman, Jeffrey ; Jain, Ajay Kumar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3574-a2f7c442127bcf28ef4e7aadd3a0cae0ab1d4aa04e798788afe6910883f22c993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cytokeratin</topic><topic>Deferoxamine</topic><topic>Donor Selection</topic><topic>Ferroptosis</topic><topic>Graft Survival</topic><topic>Humans</topic><topic>Immunomodulation</topic><topic>In Vitro Techniques</topic><topic>Iron</topic><topic>Ischemia</topic><topic>ischemia reperfusion injury</topic><topic>Liver</topic><topic>Liver - blood supply</topic><topic>Liver Function Tests</topic><topic>liver transplant</topic><topic>Liver Transplantation</topic><topic>Liver transplants</topic><topic>Organ Preservation - methods</topic><topic>Organ removal</topic><topic>Perfusion</topic><topic>Perfusion - methods</topic><topic>Reperfusion</topic><topic>Reperfusion Injury - prevention & control</topic><topic>Serology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nazzal, Mustafa</creatorcontrib><creatorcontrib>Madsen, Erik C.</creatorcontrib><creatorcontrib>Armstrong, Austin</creatorcontrib><creatorcontrib>Nispen, Johan</creatorcontrib><creatorcontrib>Murali, Vidul</creatorcontrib><creatorcontrib>Song, Eric</creatorcontrib><creatorcontrib>Voigt, Marcus</creatorcontrib><creatorcontrib>Madnawat, Himani</creatorcontrib><creatorcontrib>Welu, Adam</creatorcontrib><creatorcontrib>Manithody, Chandrashekhara</creatorcontrib><creatorcontrib>Suri, Anandini</creatorcontrib><creatorcontrib>Krebs, Joseph</creatorcontrib><creatorcontrib>Gilbert, Ester</creatorcontrib><creatorcontrib>Samaddar, Ashish</creatorcontrib><creatorcontrib>Blackall, Douglas</creatorcontrib><creatorcontrib>Carpenter, Danielle</creatorcontrib><creatorcontrib>Varma, Chintalapati</creatorcontrib><creatorcontrib>Teckman, Jeffrey</creatorcontrib><creatorcontrib>Jain, Ajay Kumar</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric transplantation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nazzal, Mustafa</au><au>Madsen, Erik C.</au><au>Armstrong, Austin</au><au>Nispen, Johan</au><au>Murali, Vidul</au><au>Song, Eric</au><au>Voigt, Marcus</au><au>Madnawat, Himani</au><au>Welu, Adam</au><au>Manithody, Chandrashekhara</au><au>Suri, Anandini</au><au>Krebs, Joseph</au><au>Gilbert, Ester</au><au>Samaddar, Ashish</au><au>Blackall, Douglas</au><au>Carpenter, Danielle</au><au>Varma, Chintalapati</au><au>Teckman, Jeffrey</au><au>Jain, Ajay Kumar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Novel NMP split liver model recapitulates human IRI and demonstrates ferroptosis modulators as a new therapeutic strategy</atitle><jtitle>Pediatric transplantation</jtitle><addtitle>Pediatr Transplant</addtitle><date>2022-03</date><risdate>2022</risdate><volume>26</volume><issue>2</issue><spage>e14164</spage><epage>n/a</epage><pages>e14164-n/a</pages><issn>1397-3142</issn><eissn>1399-3046</eissn><abstract>Background
Almost 9%of deceased donor livers are discarded as marginal donor livers (MDL) due to concern of severe ischemia reperfusion injury (IRI). Emerging data supports ferroptosis (iron regulated hepatocellular death) as an IRI driver, however lack of robust preclinical model limits therapeutic testing. In this manuscript we describe the development of a novel rigorous internal control system utilizing normothermic perfusion of split livers to test ferroptosis regulators modulating IRI.
Methods
Upon institutional approval, split human MDLs were placed on our normothermic perfusion machine, Perfusion Regulated Organ Therapeutics with Enhanced Controlled Testing (PROTECT), pumping arterial and portal blood. Experiment 1 compared right (UR) and left (UL) lobes to validate PROTECT. Experiment 2 assessed ferroptosis regulator Deferoxamine in Deferoxamine Agent Treated (DMAT) vs. No Agent Internal Control (NAIC) lobes. Liver serology, histology, and ferroptosis genes were assessed.
Results
Successful MDL perfusion validated PROTECT with no ALT or AST difference between UR and UL (∆ALT UR: 235, ∆ALT UL: 212; ∆AST UR: 576, ∆AST UL: 389). Liver injury markers increased in NAIC vs. DMAT (∆ALT NAIC: 586, ∆ALT DMAT: ‐405; ∆AST NAIC: 617, ∆AST DMAT: ‐380). UR and UL had similar expression of ferroptosis regulators RPL8,HO‐1 and HIFα. Significantly decreased intrahepatic iron (p = .038), HO‐1 and HIFα in DMAT (HO‐1 NAIC: 6.93, HO‐1 DMAT: 2.74; HIFαNAIC: 8.67, HIFαDMAT: 2.60)and no hepatocellular necrosis or immunohistochemical staining (Ki67/Cytokeratin‐7) differences were noted.
Conclusion
PROTECT demonstrates the therapeutic utility of a novel normothermic perfusion split liver system for drug discovery and rapid translatability of therapeutics, driving a paradigm change in organ recovery and transplant medicine. Our study using human livers, provides preliminary proof of concept for the novel role of ferroptosis regulators in driving IRI.</abstract><cop>Denmark</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34633130</pmid><doi>10.1111/petr.14164</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-9420-5722</orcidid><orcidid>https://orcid.org/0000-0002-8437-6085</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1397-3142 |
| ispartof | Pediatric transplantation, 2022-03, Vol.26 (2), p.e14164-n/a |
| issn | 1397-3142 1399-3046 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2580940158 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Cytokeratin Deferoxamine Donor Selection Ferroptosis Graft Survival Humans Immunomodulation In Vitro Techniques Iron Ischemia ischemia reperfusion injury Liver Liver - blood supply Liver Function Tests liver transplant Liver Transplantation Liver transplants Organ Preservation - methods Organ removal Perfusion Perfusion - methods Reperfusion Reperfusion Injury - prevention & control Serology |
| title | Novel NMP split liver model recapitulates human IRI and demonstrates ferroptosis modulators as a new therapeutic strategy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T23%3A58%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Novel%20NMP%20split%20liver%20model%20recapitulates%20human%20IRI%20and%20demonstrates%20ferroptosis%20modulators%20as%20a%20new%20therapeutic%20strategy&rft.jtitle=Pediatric%20transplantation&rft.au=Nazzal,%20Mustafa&rft.date=2022-03&rft.volume=26&rft.issue=2&rft.spage=e14164&rft.epage=n/a&rft.pages=e14164-n/a&rft.issn=1397-3142&rft.eissn=1399-3046&rft_id=info:doi/10.1111/petr.14164&rft_dat=%3Cproquest_cross%3E2626169580%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2626169580&rft_id=info:pmid/34633130&rfr_iscdi=true |